Amgen makes progress with its Horizon prize Tepezza, but there's much work left to do

[cafead]

via After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepezza—an instant blockbuster which saw a perplexing slide in just its third full year on the market.

article source